SCHEMBL22472811

SCHEMBL22472811

Cc1cc(C)n2c(C)nc(C(=O)NCc3ccc(-c4ccco4)cc3)c2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APOBEC3A P31941 1/20 0.47
ADORA2A P29274 9/20 0.46
ADORA1 P30542 8/20 0.46
ADORA3 P0DMS8 4/20 0.46
ADORA2B P29275 2/20 0.46
ALDH1A1 P00352 5/20 0.44
HPGD P15428 2/20 0.44
KDM4E B2RXH2 2/20 0.44
KLKB1 P03952 1/20 0.43
CYP1A1 P04798 1/20 0.42
KMT2A Q03164 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MEN1 O00255 2/20 0.42
MAPT P10636 2/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
PKM P14618 1/20 0.41
BLM P54132 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22472807 0.87 KDM4E (0.39) APOBEC3AADORA2AADORA1ADORA3ADORA2B
SCHEMBL22472753 0.84 APOBEC3A (0.46) APOBEC3AADORA2AADORA1ADORA3ADORA2B
SCHEMBL24477293 0.80 APOBEC3A (0.50) APOBEC3AADORA2AADORA1ADORA3ADORA2B
SCHEMBL24477299 0.80 ALDH1A1 (0.71) ADORA2AADORA1ADORA3ALDH1A1HPGD
SCHEMBL22472800 0.77 ADORA2A (0.45) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL22472813 0.76 APOBEC3A (0.46) APOBEC3AALDH1A1HPGDKDM4ECYP1A1
SCHEMBL22472808 0.75 SMN1; SMN2 (0.47) APOBEC3AHPGDCYP1A1SMN1; SMN2MAPT
SCHEMBL22472783 0.75 ALDH1A1 (0.44) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL22472767 0.75 ADORA2A (0.43) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL22472809 0.74 APOBEC3A (0.43) APOBEC3AALDH1A1HPGDKDM4ECYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3215510-B1 SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL R&D INVEST S A (PT) 2023-06-07 EP disclosed
US-10786508-B2 Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders LYSOSOMAL THERAPEUTICS INC. (US) 2020-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10786508-B2 Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders GBA1, GAA, SNCA APOBEC3A 184/4885ADORA2A 234/4885ADORA1 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.